BRAF signaling pathway and targeted therapies in the BRAF pathway
The BRAF signaling pathway and targeted therapies in the BRAF pathway. Description: Binding of ligands to transmembrane receptors, such as FGFR or EGFR, leads to receptor dimerization and phosphorylation of kinases, which leads to the recruitment of growth factor receptor-bound protein 2 (GRB2) to the phosphorylated receptor. The attachment of Son of Sevenless (SOS—GTP exchange factor) to GRB2 enables the activation of RAS-GDP to RAS-GTP. The active form of RAS-GTP causes downstream activation of MAPK, PI3K, and other effector pathways. BRAF inhibitors in yellow box and MEK inhibitors in blue box inhibit BRAF and MEK substrates and inhibit downstream pathway activation
Publication
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers (2024)
Khine S. Shan, et al. Int J Mol Sci. 2024 Jan;25(1). Figure: F1.
Homo sapiens
Organism
Group
Word
Match
Source
NCBI Symbol
NCBI ID
Homo sapiens
Primates
GRB2
GRB2
ncbigene_symbol
GRB2
2885
Homo sapiens
Primates
RAS-GTP
RAS
famplex_relations
KRAS
3845
Homo sapiens
Primates
RAS-GTP
RAS
famplex_relations
HRAS
3265
Homo sapiens
Primates
RAS-GTP
RAS
famplex_relations
NRAS
4893
Homo sapiens
Primates
BRAF
BRAF
ncbigene_symbol
BRAF
673
Homo sapiens
Primates
AKT
AKT
ncbigene_synonym
AKT1
207
Homo sapiens
Primates
AKT
AKT
famplex_relations
AKT2
208
Homo sapiens
Primates
AKT
AKT
famplex_relations
AKT3
10000
Homo sapiens
Primates
MEK
MEK
ncbigene_synonym
MAP2K7
5609
Homo sapiens
Primates
MEK
MEK
famplex_relations
MAP2K1
5604
Homo sapiens
Primates
MEK
MEK
famplex_relations
MAP2K2
5605
Homo sapiens
Primates
mTOR
MTOR
ncbigene_symbol
MTOR
2475
Homo sapiens
Primates
ERK
ERK
ncbigene_synonym
EPHB2
2048
Homo sapiens
Primates
ERK
ERK
ncbigene_synonym
MAPK1
5594
Homo sapiens
Primates
ERK
ERK
famplex_relations
MAPK3
5595
Word
Match
MeSH
Name
ChEBI
Ligands
ligands
chebi:52214
effector
effector
effector
chebi:35224
Vemurafenib
vemurafenib
N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
chebi:63637
Dabrafenib
dabrafenib
N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
chebi:75045
DAY101
DAY101
6-amino-5-chloro-N-[(1R)-1-(5-{[5-chloro-4-(trifluoromethyl)pyridin-2-yl]carbamoyl}-1,3-thiazol-2-yl)ethyl]pyrimidine-4-carboxamide
chebi:167672
MEK
MEK
butan-2-one
chebi:28398
Trametinib
trametinib
N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide
chebi:75998
Binimetinib
binimetinib
5-(4-bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
chebi:145371
Cobimetinib
cobimetinib
bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate
chebi:90853
Disease mentions
Word
Match
MeSH
Name
DOID